28-04-2025, 20:23

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -
Globe Newswire28-04-2025, 20:23
23-04-2025, 14:30

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Notified -
Globe Newswire23-04-2025, 14:30
3-04-2025, 14:00

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Notified -
Globe Newswire3-04-2025, 14:00
25-09-2024, 21:45

Boehringer Ingelheim expands cancer research at its Vienna site
Globe Newswire25-09-2024, 21:45